Verification Study and Reactivity Study for the Validity of QuQu Scale
NCT ID: NCT02667665
Last Updated: 2017-06-02
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
240 participants
OBSERVATIONAL
2016-02-19
2016-11-15
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Exploratory Study for the Validity of QuQu Scale
NCT02267486
DIagnostic Biomarkers and Symptoms in Patients With Alzheimer's Disease and Lewy bodY Dementia
NCT05768425
A Home-based Training Program for Elderly Patients With Dementia
NCT02667951
Application of AI Technology for the Diagnosis and Treatment of Geriatric Diseases
NCT06295263
Evaluation of Adherence and Engagement in a Cognitive Training Program for Older Adults
NCT03262506
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Alzheimer's Disease Dementia
No interventions assigned to this group
non-Dementia
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Written Informed consent by each subject and/or a legal representative, and study informant. If the doctor decides that the patient has no trouble in understanding this study, the written informed consent of a legal representative may be exempted. If not, this study needs a written informed consent by a legal representative and the patient except the case where the consent is hardly obtained due to the progression of the disease.
Exclusion Criteria
2. patients with other diseases which cause secondary dementia prior to Alzheimer's Disease Dementia
3. patients with other severe neurological disease or psychiatric disorder without Alzheimer's Disease Dementia
4. patients with other medical conditions where the investigators determine that it is inappropriate for the subject of this study (e.g. inappropriate for the evaluation of dementia rating scale)
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Daiichi Sankyo Co., Ltd.
INDUSTRY
Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Yu Nakamura, Professor
Role: STUDY_CHAIR
Kagawa University School of Medicine
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Kagawa University School of Medicine
Kitagun, Kagawa-ken, Japan
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
TRIAD1412
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.